Tevimbra (tislelizumab-jsgr) — Medica

Initial criteria

• age ≥ 18 years
• ONE of the following: (i) BOTH of: locally recurrent, progressive disease and administered before abdominoperineal resection; OR (ii) ALL of: metastatic disease, used as subsequent therapy, no prior immunotherapy
• used as single agent
• prescribed by or in consultation with an oncologist

Approval duration

1 year